COVID-19 Outbreak-Global Plasma Protein Therapeutics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
- 116 Pages
- Region: Global
Plasma is the liquid parts of blood that residue once platelets, white and red blood cells and various other cellular components are detached. In human blood, only plasma is the largest component and contains proteins, antibodies, enzymes, salts, and water. Plasma is the protein-rich fluids that defer cells in human blood and achieves various essential transport functions. The proteins that originate in plasma plays an important function in clotting and provide immunity to diseases. Plasma proteins are used in many conditions for treatment such as shocks & burns, neurological & bleeding disorders, autoimmune and immune deficiencies. Plasma protein therapies is a unique biological medicine which contains biological starting material called plasma which has a unique biochemical profile which differs in processing methods and production methods. Plasma protein therapies are used to treat various genetic, chronic, life-threatening and rare diseases.
The Plasma Protein Therapeutics market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.
Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.
In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Plasma Protein Therapeutics industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.
The Plasma Protein Therapeutics market can be split based on product types, major applications, and important countries as follows:
Key players in the global Plasma Protein Therapeutics market covered in Chapter 12:
Octapharma USA, Inc.
China Biologic Products Holdings, Inc.
Kedrion S.P.A. \
In Chapter 4 and 14.1, on the basis of types, the Plasma Protein Therapeutics market from 2015 to 2025 is primarily split into:
C1 esterase Inhibitors
In Chapter 5 and 14.2, on the basis of applications, the Plasma Protein Therapeutics market from 2015 to 2025 covers:
Primary Immunodeficiency Disorder
Idiopathic Thrombocytopenic Purpura
Secondary Immunodeficiency (CLL, multiple myeloma, congenital aids)
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
Europe (Covered in Chapter 8 and 14)
Asia-Pacific (Covered in Chapter 9 and 14)
Middle East and Africa (Covered in Chapter 10 and 14)
South America (Covered in Chapter 11 and 14)
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025